Current and Future Therapeutic Approaches to Hyperlipidemia

Advances in Pharmacology

Volumn 35, Issue C, 1996, Pages 79-114

  Farmer, John A ^a   Gotto Jr , Antonio M ^a  

^a BEN TAUB GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; REVIEW;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS;

EID: 0029684071     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60275-6     Document Type: Article

References (125)

1. Abbey M., Clifton P., Kestin M., Belling B., and Nestel P. Effect of fish oil on lipoproteins, lecithin: cholesterol acyltransferase, and lipid transfer protein activity in humans. Arteriosclerosis 10 (1990) 85-94
2. Andersen P., Smith P., Seljeflot I., Brataker S., and Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb. Haemost. 63 (1990) 174-177
3. Arad Y.-, Ramakrishnan R., and Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production. J. Lipid Res. 31 (1990) 567-582
4. Asano T., Pollard M., and Madsen D.C. Effect of cholestyramine on 1,2-dimethylhydrazine-induced enteric carcinoma in germfree rats. Proc. Soc. Exp. Biol. Med. 150 (1975) 780-785
5. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am. J. Cardiol. 70 (1992) 733-737
6. Austin M.A. Plasma triglyceride as a risk factor for coronary heart disease: The epidemiologic evidence and beyond. Am. J. Epidemiol. 129 (1989) 249-259
7. Austin M.A. Plasma triglyceride and coronary heart disease. Arterioscler. Thromb. 11 (1991) 2-14
8. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
9. Baker S.G., Joffe B.I., Mendelsohn D., and Seftel H.C. Treatment of homozygous familial hypercholesterolemia with probucol. S. Afr. Med. J. 62 (1982) 7-11
10. Bang H.O., and Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med. Scand. 192 (1972) 85-94
11. Bazzano G., and Bazzano G.S. Digitalis intoxication. Treatment with a new steroid-binding resin. JAMA 220 (1972) 828-830
12. Beil F.U., Schrameyer-Wernecke A., Beisiegel U., Greten H., Karkas J.D., Liou R., Alberts A.W., Eckardt H.G., and Till A.E. Lovastatin versus bezafibrate: Efficacy, tolerability, and effect on urinary mevalonate. Cardiology 77 Suppl. 4 (1990) 22-32
13. Bergstrom J.D., Kurtz M.M., Rew D.J., Amend A.M., Karkas J.D., Bostedor R.G., Bansal V.S., Dufresne C., VanMiddlesworth F.L., Hensens O.D., Liesch J.M., Zink D.L., Wilson K.E., Onishi J., Milligan J.A., Bills G., Kaplan L., NallinOmstead M., Jenkins R.G., Huang L., Meinz M.S., Quinn L., Burg R.W., Kong Y.L., Mochales S., Mojena M., Martin I., Pelaez F., Diez M.T., and Alberts A.W. Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 80-84
14. Berndt J., Gaumert R., and Still J. Mode of action of the lipid-lowering agents, clofibrate and BM15075, on cholesterol biosynthesis in rat liver. Atherosclerosis 30 (1978) 147-152
15. Black D. Atorvastatin: A step ahead for HMG-CoA reductase inhibitors. Atherosclerosis 109 (1994) 88-89 [Abstract]
16. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., and Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987) 3233-3240
17. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., and Azen S.P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipid and nonlipid factors. Circulation 81 (1990) 470-476
18. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L., Hodis H.N., DeBoer L.W.V., Mahrer P.R., Masteller M.J., Vailas L.I., Alaupovic P., Hirsch L.J., and andthe MARS Research Group. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. 119 (1993) 969-976
19. Braden G.A., Knapp H.R., and FitzGerald G.A. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 84 (1991) 679-685
20. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould A.L., Hesney M., Higgins J., Hurley D.P., Langendorfer A., Nash D.T., Pool J.L., and Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151 (1991) 43-49
21. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C.A., Franklin F.A., Grillo R.B., Higgins J., Langendorfer A., Nash D.T., Pool J.L., and Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am. J. Cardiol. 74 (1994) 667-673
22. Brensike J.F., Kelsey S.F., Passamani E.R., Fisher M.R., Richardson J.M., Loh I.K., Stone N.J., Aldrich R.F., Battaglini J.W., Moriarty D.J., Myrianthopoulos M.B., Detre K.M., Epstein S.E., and Levy R.I. National Heart, Lung, and Blood Institute Type II Coronary Intervention Study: Design, methods, and baseline characteristics. Controlled Clin. Trials 3 (1982) 91-111
23. Brensike J.F., Levy R.I., Kelsey S.F., Passamani E.R., Richardson J.M., Loh I.K., Stone N.J., Aldrich R.F., Battaglini J.W., Moriarty D.J., Fisher M.R., Friedman L., Friedewald W., Detre K.M., and Epstein S.E. Effects of therapy with cholestyr-amine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 69 (1984) 313-324
24. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.-T., Kaplan C., Zhao X.-Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323 (1990) 1289-1298
25. Brown M.S., Goldstein J.L., Havel R.J., and Steinberg D. Gene therapy for cholesterol [letter]. Nat. Genet. 7 (1994) 349-350
26. Brown W.V., Howard W.J., and Field L. Nicotinic acid and its derivatives. In: Rifkind B.M. (Ed). "Drug Treatment of Hyperlipidemia" (1991) 189-213
27. Buckley M.M.-T., Goa K.L., Price A.H., and Brogden R.N. Probucol: A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 37 (1989) 761-800
28. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedewald W., and forthe Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J. Am. Coll. Cardiol. 8 (1986) 1245-1255
29. Carew T.E., Schwenke D.C., and Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7725-7729
30. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223 (1988) 405-418
31. Carlson L.A., Hamsten A., and Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J. Intern. Med. 226 (1989) 271-276
32. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., and Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis: A 4-year follow-up. JAMA 264 (1990) 3013-3017
33. Chappell D.A., Fry G.L., Waknitz M.A., Muhonen L.E., and Pladet M.W. Low density lipoprotein receptors bind and mediate cellular catabolism of normal very low density lipoproteins in vitro. J. Biol. Chem. 268 (1993) 25487-25493
34. Charman R.C., Matthews L.B., and Braeuler C. Nicotinic acid in the treatment of hypercholesterolemia: A long term study. Angiology 23 (1972) 29-35
35. Chung B.H., Segrest J.P., Smith K., Griffin F.M., and Brouillette C.G. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein: A possible mechanism of atherogenesis?. J. Clin. Invest. 83 (1989) 1363-1374
36. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 40 (1978) 1069-1118
37. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Lancet 2 (1984) 600-604
38. Constantino M., Merskey C., Kudzma D.J., and Zucker M.B. Increased activity of vitamin K-dependent clotting factors in human hyperlipoproteinaemia-association with cholesterol and triglyceride levels. Thromb. Haemost. 38 (1977) 465-474
39. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
40. Corpier C.L., Jones P.H., Suki W.N., Lederer E.D., Quinones M.A., Schmidt S.W., and Young J.B. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 260 (1988) 239-241
41. Crutchley D.J., McPhee G.V., Terris M.F., and Canossa-Terris M.A. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 9 (1989) 934-939
42. Dachet C., Jacotot B., and Buxtorf J.C. The hypolipidemic action of probucol: Drug transport and lipoprotein composition in type Ha hyperlipoproteinemia. Atherosclerosis 58 (1985) 261-268
43. Davignon J. Fibrates: Areview of important issues and recent findings. Can. J. Cardiol. 10 Suppl B (1994) 61B-71B
44. Dolecek T.A. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial. Proc. Soc. Exp. Biol. Med. 200 (1992) 177-182
45. Dujovne C.A., Atkins F., Wong B., DeCoursey S., Krehbiel P., and Chernoff S.B. Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur. J. Clin. Pharmacol. 26 (1984) 735-739
46. Eisenberg S., Gavish D., Oschry Y., Fainaru M., and Deckelbaum R.J. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: Reversal toward normal with bezafibrate treatment. J. Clin. Invest. 74 (1984) 470-482
47. Endo A., Kuroda M., and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot. (Tokyo) 29 (1976) 1346-1348
48. Eto M., Sato T., Watanabe K., Iwashima Y., and Makino I. Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4. Atherosclerosis 84 (1990) 49-53
49. Forland S.C., Feng Y., and Cutler R.E. Apparent reduced absorption of gemfibrozil when given with colestipol. J. Clin. Pharmacol. 30 (1990) 29-32
50. Franceschini G., Sirtori M., Gianfranceschi G., Frosi T., Montanari G., and Sirtori C.R. Reversible increase of the apo Cll/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Artery 12 (1985) 363-381
51. Franceschini G., Sirtori M., Vaccarino V., Gianfranceschi G., Rezzonico L., Chiesa G., and Sirtori C.R. Mechanisms of HDL reduction after probucol: Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 9 (1989) 462-469
52. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., and Nikkilä E.A. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317 (1987) 1237-1245
53. Gallo D.G., Bailey K.R., and Sheffner A.L. The interaction between cholestyramine and drugs. Proc. Soc. Exp. Biol. Med. 120 (1965) 60-65
54. Gass J.D. Nicotinic acid maculopathy. Am. J. Ophthalmol. 76 (1973) 500-510
55. Gianturco S.H., Bradley W.A., Nozaki S., Vega G.L., and Grundy S.M. Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia. Arterioscler. Thromb. 13 (1993) 472-481
56. Gilligan D.M., Guetta V., Panza J.A., García C.E., Quyyumi A.A., and Cannon III R.O. Selectiveloss of microvascular endothelial function in human hypercholesterolemia. Circulation 90 (1994) 35-41
57. Glueck C.J., Oakes N., Speirs J., Tracy T., and Lang J. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am. J. Cardiol. 70 (1992) 1-9
58. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62 (1977) 707-714
59. Gotto Jr. A.M. Postmenopausal hormone-replacement therapy, plasma lipoprotein [a], and risk for coronary heart disease [editorial]. J. Lab. Clin. Med. 123 (1994) 800
60. Granfone A., Campos H., McNamara J.R., Schaefer M.M., Lamon-Fava S., Ordovas J.M., and Schaefer E.J. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 41 (1992) 1193-1198
61. Grossman M., Raper S.E., Kozarsky K., Stein E.A., Engelhardt J.F., Muller D., Lupien P.J., and Wilson J.M. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6 (1994) 335-341
62. Grundy S.M. HMG CoA reductase inhibitors: Clinical applications and therapeutic potential. In: Rifkind B.M. (Ed). "Drug Treatment of Hyperlipidemia" (1991) 139-167
63. Hibbard D.M., Peters J.R., and Hunninghake D.B. Effects of cholestyramine and colestipol on the plasma concentrations of propranolol. Br. J. Clin. Pharmacol. 18 (1984) 337-342
64. Hidaka Y., Hotta H., Nagata Y., Iwasawa Y., Horie M., and Kamei T. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells. J. Biol. Chem. 266 (1991) 13171-13177
65. Hunninghake D.B., King S., and LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int. J. Clin. Pharmacol. Ther. Toxicol. 20 (1982) 151-154
66. Huttunen J.K., Manninen V., Mänttäri M., Koskinen P., Romo M., Tenkanen L., Heinonen O.P., and Frick M.H. The Helsinki Heart Study: Central findings and clinical implications. Ann. Med. 23 (1991) 155-159
67. Illingworth D.R. Fibric acid derivatives. In: Rifkind B.M. (Ed). "Drug Treatment of Hyperlipidemia" (1991), Marcel Dekker, New York. 103-138
68. Illingworth D.R., and Tobert J.A. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther. 16 (1994) 366-385
69. Isaacsohn J.L., Setaro J.F., Nicholas C., Davey J.A., Diotalevi L.J., Christianson D.S., Liskov E., Stein E.A., and Black H.R. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am. J. Cardiol. 74 (1994) 735-737
70. Kannel W.B. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am. Heart J. 114 (1987) 413-419
71. Kaplan R., Aynedjian H.S., Schlondorff D., and Bank N. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J. Clin. Invest. 86 (1990) 1707-1714
72. Kesäniemi Y.A., and Grundy S.M. Influence of probucol on cholesterol and lipoprotein metabolism in man. J. Lipid Res. 25 (1984) 780-790
73. Kirby T.J. Cataracts produced by triparanol. Trans. Am. Ophthalmol. Soc. 65 (1967) 493-543
74. Kostner G.M., Gavish D., Leopold B., Bolzano K., Weintraub M.S., and Breslow J.L. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80 (1989) 1313-1319
75. Kozarsky K.F., McKinley D.R., Austin L.L., Raper S.E., Stratford-Perricaudet L.D., and Wilson J.M. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269 (1994) 13695-13702
76. Krause B.R., Pape M.E., Kieft K., Auerbach B., Bisgaier C.L., Homan R., and Newton R.S. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterolfree diet: Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler. Thromb. 14 (1994) 598-604
77. Langer T., and Levy R.I. Acute muscular syndrome associated with administration of clofibrate. N. Engl. J. Med. 279 (1968) 856-858
78. Lehr H.A., Hubner C., Nolte D., Kohlschutter A., and Messmer K. Dietary fish oil blocks the microcirculatory manifestations of ischemia-reperfusion injury in striated muscle in hamsters. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 6726-6730
79. Lemarchand P., Jones M., Yamada I., and Crystal R.G. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ. Res. 72 (1993) 1132-1138
80. Levy R.I., Morganroth J., and Rifkind B.M. Treatment of hyperlipidemia. N. Engl. J. Med. 290 (1976) 1295-1301
81. Li Q., Kay M.A., Finegold M., Stratford-Perricaudet L.D., and Woo S.L. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4 (1993) 403-409
82. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
83. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365-374
84. Litin S.C., and Anderson C.F. Nicotinic acid-associated myopathy: A report of three cases. Am. J. Med. 86 (1989) 481-483
85. Loscalzo J. Lipoprotein(a): A unique risk factor for atherothrombotic disease. Arteriosclerosis 10 (1990) 672-679
86. MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638
87. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mänttäri M., Heinonen O.P., and Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 85 (1992) 37-45
88. Millay R.H., Klein M.L., and Illingworth D.R. Niacinmaculopathy. Ophthalmology 95 (1988) 930-936
89. 14C and its degradation products in a hypercholesterolemic patient. J. Clin. Invest. 47 (1968) 1664-1671
90. Morris M.C., Sacks F., and Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88 (1993) 523-533
91. Mullin G.E., Greenson J.K., and Mitchell M.C. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann. Intern. Med. 111 (1989) 253-255
92. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89 (1994) 1329-1445
93. Nestel P.J., Connor W.E., Reardon M.F., Connor S., Wong S., and Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J. Clin. Invest. 74 (1984) 82-89
94. Newman W.P., Middaugh J.P., Propst M.T., and Rogers D.R. Atherosclerosis in Alaska Natives and non-natives. Lancet 341 (1993) 1056-1057
95. Nikkila E.A., Huttunen J.K., and Ehnholm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 26 (1977) 179-186
96. Patsch J.R., Miesenböck G., Hopferwieser T., Mühlberger V., Knapp E., Dunn J.K., Gotto Jr. A.M., and Patsch W. Relation of triglyceride metabolism and coronary artery disease: Studies in the postprandial state. Arterioscler. Thromb. 12 (1992) 1336-1345
97. Pierce L.R., Wysowski D.K., and Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264 (1990) 71-75
98. Pitt B., Mancini G.B.J., Ellis S.G., Rosman H.S., Park J.-S., McGovern M.E., and for the PLACI Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I) reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26 (1995) 1133-1139
99. Rader J.I., Calvert R.J., and Hathcock J.N. Hepatic toxicity of unmodified and time-release preparations of niacin. Am. J. Med. 92 (1992) 77-81
100. Reaven P., and Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis [letter]. Ann. Intern. Med. 109 (1988) 597-598
101. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
102. Schmidt E.B., Illingworth D.R., Bacon S., Russell S.J., Thatcher S.R., Mahley R.W., and Weisgraber K.H. Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. Metabolism 42 (1993) 137-139
103. Shepherd J., Packard C.J., Patsch J.R., Gotto Jr. A.M., and Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest. 63 (1979) 858-867
104. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlene P.W., McKillop J.H., Packard C.J., and for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333 (1995) 1301-1307
105. Simpson H.S., Williamson C.M., Olivecrona T., Pringle S., Maclean J., Lorimer A.R., Bonnefous F., Bogaievsky Y., Packard C.J., and Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 85 (1990) 193-202
106. Sirtori C.R., Calabresi L., Werba J.P., and Franceschini G. Tolerability of fibric acids. Comparative data and biochemical bases. Pharmacol. Res. 26 (1992) 243-260
107. Sliskovic D.R., and White A.D. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci. 12 (1991) 194-199
108. Soma M.R., Osnago-Gadda I., Paoletti R., Fumagalli R., Morrisett J.D., Meschia M., and Crosignani P. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch. Intern. Med. 153 (1993) 1462-1468
109. Spach D.H., Bauwens J.E., Clark C.D., and Burke W.G. Rhabdomyolysis associated with lovastatin and erythromycin use. West J. Med. 154 (1991) 213-216
110. Tilly-Kiesi M., and Tikkanen M.J. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J. Intern. Med. 229 (1991) 427-434
111. Tobert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62 (1988) 28J-34J
112. Tobert J.A., Shear C.L., Chremos A.N., and Mantell G.E. Clinical experience with lovastatin. Am. J. Cardiol. 65 (1990) 23F-26F
113. Todd P.A., and Ward A. Gemfibrozil: A review of its pharmacodynamic and pharma-cokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36 (1988) 314-339
114. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., and Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332 (1995) 481-487
115. Wada H., Mori Y., Kaneko T., Wakita Y., Nakase T., Minamikawa K., Ohiwa M., Tamaki S., Tanigawa M., Kageyama S., Deguchi K., Nakano T., Shirakawa S., and Suzuki K. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am. J. Hematol. 44 (1993) 112-116
116. Wagner J.D., St Clair R.W., Schwenke D.C., Shively C.A., Adams M.R., and Clarkson T.B. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Effects of estrogen and progesterone replacement therapy. Arterioscler. Thromb. 12 (1992) 717-726
117. Walldius G., Regnström J., Nilsson J., Johansson J., Schäfer-Elinder L., Moelgaard J., Hådell K., Olsson A.G., and Carlson L.A. The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 71 (1993) 15B-19B
118. Walldius G., Erikson U., Olsson A.G., Bergstrand L., Hådell K., Johansson J., Kaijser L., Lassvik C., Mölgaard J., Nilsson S., Schäfer-Elinder L., Stenport G., and Holme I. The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 74 (1994) 875-883
119. Waters D., Higginson L., Gladstone P., Kimball B., LeMay M., Boccuzzi S.J., Lespérance M., and the CCATT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 (1994) 959-968
120. Watts G.F., Lewis B., Brunt J.N.H., Lewis E.S., Coltart D.J., Smith L.D.R., Mann J.I., and Swan A.V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339 (1992) 563-569
121. Wiklund O., Angelin B., Bergman M., Berglund L., Bondjers G., Carlsson A., Lindén T., Miettinen T., Ödman B., Olofsson S.-O., Saarinen I., Sipilä R., Sjöström P., Kron B., Vanhanen H., and Wright I. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am. J. Med. 94 (1993) 13-20
122. Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) trial. JAMA 273 (1995) 199-208
123. Yamamoto A., Matsuzawa Y., Yokoyama S., Funahashi T., Yamamura T., and Kishino B.O.-I. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am. J. Cardiol. 57 (1986) 29H-35H
124. Ying H., Saku K., Harada R., Takami N., Sasaki N., Saito Y., and Arakawa K. Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoproteins kinetics in rabbits. Biochim. Biophys. Acta 1047 (1990) 247-254
125. Zilversmit D.B. Atherogenesis: A postprandial phenomenon. Circulation: 60 (1979) 473-485